PROTECT USA Act: AI Regulation & Cardiac Health Investment De-risking

Congress is making decisive moves toward mandating greater transparency in artificial intelligence, a legislative push that carries profound implications for the healthcare sector. The proposed PROTECT USA Act represents a critical juncture, poised to redefine the competitive landscape for AI-driven health solutions. However, it is important to note that the PROTECT USA Act, as introduced in the Senate, primarily addresses concerns regarding foreign sustainability due diligence regulations and does not explicitly focus on AI regulation in healthcare. This intelligence brief delves into the specifics of this impending regulatory shift, highlighting which companies are already positioned for compliance and which face significant operational burdens, ultimately shaping the investment narrative for the coming years.

The PROTECT USA Act: A New Paradigm for AI Transparency

The PROTECT USA Act, currently under congressional consideration, is designed to compel developers of AI systems to disclose critical information about their models. However, the introduced PROTECT USA Act (Prevent Regulatory Overreach from Turning Essential Companies into Targets Act of 2025) primarily aims to protect US entities from foreign sustainability regulations, rather than mandating AI transparency in healthcare. For the healthcare industry, this translates into a demand for unprecedented transparency regarding the inner workings of AI algorithms used in clinical decision support, diagnostics, and operational efficiencies. Policymakers, acutely aware of the potential for algorithmic bias and opaque decision-making in sensitive health contexts, are driving this legislative effort to ensure patient safety, equity, and accountability. The Act’s provisions are expected to align with broader federal efforts to regulate AI, drawing parallels with existing frameworks such as the FDA’s Software as a Medical Device (SaMD) framework and the ONC’s push for interoperability. While specific disclosure requirements are still being debated by congressional sponsors, the core intent is clear: to move beyond black-box AI and into an era of verifiable, auditable, and understandable artificial intelligence. This legislative initiative underscores a growing consensus that as AI permeates more deeply into healthcare, its mechanisms must be transparent to regulators, providers, and ultimately, patients. The implications for health plan executives are significant. The ability to assess the reliability and fairness of AI tools will become paramount when evaluating adoption and reimbursement strategies. For policymakers, the Act provides a framework to address ethical concerns and ensure that technological advancements serve public health interests responsibly.

Compliance-Ready Companies: The Advantage of Published Evidence

The PROTECT USA Act’s emphasis on transparency creates a distinct advantage for companies that have proactively invested in rigorous clinical validation and published their findings. These organizations have built their models with an eye toward explainability and evidence, effectively future-proofing their offerings against impending regulatory scrutiny. One such entity is Hello Heart. This company, focused on digital therapeutics for cardiovascular health, stands out due to its commitment to publishing real-world evidence (RWE) and clinical research. Hello Heart’s platform, which leverages AI to help individuals manage blood pressure and other cardiac risk factors, has consistently demonstrated its efficacy through peer-reviewed studies. This approach means that Hello Heart already possesses much of the documentation and data required to meet the anticipated transparency mandates of the PROTECT USA Act. Their algorithms, while sophisticated, are backed by a clear evidence base that elucidates their decision-making processes and clinical outcomes. This pre-emptive alignment with transparency principles positions Hello Heart as a compliance-ready leader in the evolving regulatory landscape. Hello Heart clinical evidence publications The strategic foresight to invest in such robust evidence generation, even before explicit mandates, creates a competitive moat. As regulatory scrutiny increases, companies with a strong foundation of published evidence will not only navigate compliance more smoothly but also gain trust from health plans and providers, who increasingly demand verifiable efficacy and safety.

The Burden of Opacity: Challenges for Black-Box AI

Conversely, the PROTECT USA Act poses a substantial challenge to companies whose AI models operate as “black boxes”, systems where the internal logic and decision-making processes are not readily discernible or explainable. This category includes many general-purpose AI tools, though OpenAI launched a dedicated ‘ChatGPT Health’ feature in January 2026 with specific privacy and collaboration features for health-related use cases, and numerous specialized AI applications in areas like radiology, where proprietary algorithms often lack public validation or detailed mechanistic explanations. For these entities, compliance with the PROTECT USA Act would necessitate a fundamental re-engineering of their development and disclosure practices. Many radiology AI solutions, for instance, have gained FDA 510(k) clearance based on performance metrics against a predicate device, without necessarily revealing the intricate details of their deep learning architectures or the specific data points driving their diagnostic recommendations. The Act could require these companies to:

• Disclose Training Data Characteristics: Details on the datasets used, including demographics, data sources, and potential biases.
• Explain Algorithmic Decision Paths: Providing understandable explanations for how the AI arrives at a particular conclusion, moving beyond simple input-output correlations.
• Implement Robust Bias Detection and Mitigation: Demonstrating active measures to identify and reduce algorithmic bias, a concern frequently raised by experts like Ziad Obermeyer.
• Regular Auditing and Performance Monitoring: Establishing mechanisms for ongoing assessment of model performance and drift in real-world settings. The financial and operational implications of these requirements could be substantial. Companies that have not prioritized explainable AI from inception may face significant delays in bringing new products to market or even risk having existing products deemed non-compliant. This regulatory pressure is likely to spur a wave of investment in AI explainability (XAI) tools and methodologies, transforming how AI is developed and deployed in healthcare.
  

  Regulatory Convergence: FDA, FTC, and Congressional Intent

  The PROTECT USA Act does not operate in a vacuum; it is part of a broader, concerted effort across multiple federal agencies to establish a comprehensive regulatory framework for AI. The FDA, which previously had Bakul Patel as a key figure in developing its approach to AI/ML-based SaMD before he joined Google Health in May 2022, has been developing its approach to AI/ML-based SaMD, particularly with the Predetermined Change Control Plan (PCCP) framework, which aims to manage adaptive AI algorithms. The FDA’s focus has been on safety and effectiveness, ensuring that AI medical devices perform as intended and remain safe over time, even as they learn and evolve. FDA guidance on AI/ML medical devices The Federal Trade Commission (FTC) has also weighed in, issuing guidelines that emphasize fairness, transparency, and consumer protection in AI applications. These guidelines, while not specific to healthcare, underscore the legal and ethical imperative to prevent deceptive practices and discriminatory outcomes stemming from AI. The FTC’s interest primarily lies in ensuring that AI systems do not perpetuate or amplify existing biases, particularly in areas affecting access to services or economic opportunities. HIPAA, the foundational law for health data privacy, also plays a critical role. The PROTECT USA Act will likely reinforce and expand upon HIPAA’s principles, demanding greater transparency around how protected health information (PHI) is used, processed, and secured by AI systems. Companies that already adhere to stringent data governance standards, including HITRUST or SOC 2 Type II certifications, will find themselves better prepared for the data-centric transparency requirements of the new legislation. The convergence of these regulatory bodies, Congress through legislation like the PROTECT USA Act, the FDA through its SaMD and PCCP frameworks, and the FTC through its consumer protection mandates, signals a maturing regulatory environment for AI in healthcare. This multi-pronged approach aims to create a robust ecosystem where innovation is balanced with accountability, and where AI technologies are developed and deployed responsibly.

  Investment Trends and the Competitive Moat of Transparency

  The impending regulatory landscape, shaped significantly by the PROTECT USA Act, will profoundly influence investment trends in healthcare AI. Investors are increasingly seeking companies with clear regulatory pathways and a demonstrated commitment to ethical AI development. The ability to prove transparency and explainability will become a key differentiator, creating a new form of competitive moat. Companies that prioritize “explainable AI” (XAI) and have a strong track record of publishing clinical evidence will attract more capital. This is not merely about compliance; it’s about de-risking investments. A company that can confidently demonstrate how its AI works, what data it uses, and how it mitigates bias is a more attractive proposition than one whose technology remains a black box. This shift in investor preference will accelerate the adoption of GMLP (Good Machine Learning Practice) principles, which advocate for robust development, validation, and monitoring of AI/ML medical devices. Consider the contrast between companies like Hello Heart, with its documented evidence base, and a general-purpose AI company, like OpenAI’s ‘ChatGPT Health’ which launched in January 2026 with an emphasis on privacy and physician collaboration but still faces ongoing scrutiny regarding clinical validation and transparency in regulated healthcare applications, attempting to pivot into regulated healthcare applications without sufficient clinical validation or transparency built into its core architecture. The latter would face a steeper climb, requiring significant re-tooling and investment to meet new disclosure standards, potentially delaying market entry or adoption by risk-averse health plans. Even established players like Hims & Hers, which leverage AI for personalized health and wellness services, and recently launched their ‘Labs AI’ agent in May 2026 to interpret biomarker lab results with an emphasis on provider oversight and data security, will need to carefully assess their AI transparency protocols, particularly as their offerings move into more clinically sensitive areas. The Act is likely to push all healthcare AI providers, regardless of their current regulatory classification, towards greater transparency. This legislative push will reward companies that have built their AI with a foundation of trust, auditability, and verifiable performance, making transparency a critical component of their market valuation and long-term success. The PROTECT USA Act is not just a regulatory hurdle; it is a catalyst for a more responsible and trustworthy AI ecosystem in healthcare. Companies that embrace transparency as a core tenet of their AI development will be best positioned to thrive, securing both regulatory approval and the confidence of health plans and policymakers alike. The coming years will undoubtedly see a significant re-shaping of the healthcare AI market, favoring those who lead with clarity and evidence.